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Abstract
The aim of this study was to determine the seroprevalence of Brucella spp. in a 
goat flock and the seroconversion of three groups of animals vaccinated with Rev-1 
(Brucella melitensis), RB51, and RB51-SOD (Brucella abortus) to estimate the level 
of protection conferred on susceptible females. Seventy-two animals were used 
by group. Goats were older than 3 months, seronegative to brucellosis, not vac-
cinated previously, and kept within positive flocks. Vaccinated animals received 
2 mL of product subcutaneously in the neck region. The first block was injected 
with Rev-1; the second received RB51, and the third group was injected with 
RB51-SOD. Follow-up sampling was performed at 30, 60, 90, and 365 days post-
vaccination. The general prevalence of brucellosis for the three groups was 1.2% 
(95%CI:0.5–2.7). The seroconversion rate by day 30 after vaccination was 77.7% 
(95%CI:61.9–88.2) for goats vaccinated with Rev-1. At 365 days post vaccination, 
the percentage of seropositive goats declined to 13.8% (95%CI:6.0–28.6). At day 365 
after vaccination, 2.7% (95%CI:0.4–14.1) and 5.5% (95%CI:1.5–18.1) of animals 
vaccinated with RB51 and RB51-SOD, respectively, became positive. Results show 
that the seroconversion induced by Brucella abortus RB51 and RB51-SOD vaccines is 
lower than that by Brucella melitensis Rev-1.
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1. Introduction
The brucellosis is a highly contagious disease and one of the zoonoses world-
wide; most importantly, it is caused by bacteria of the genus Brucella [1]. This has 
been classified by the World Health Organization (WHO) as one of the “top 10” 
neglected zoonoses, a group of diseases that are simultaneously ongoing threats to 
human health and a source of perpetuation for poverty [2]. The importance of the 
disease is enormous but remains under-prioritized worldwide, especially among 
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the pastoralists and small-scale livestock farmers. The humans can be infected by 
ingestion of food products such as unpasteurized milk and their derivative products 
contaminated with the pathogen or by direct interaction with an infected animal or 
by aerosol inhalation [1, 3].
In small ruminants, the brucellosis is caused by B. melitensis [4, 5], the most 
important agent that induces the disease in humans [6, 7]. The disease often occurs 
in cattle, sheep, and goat production units; the latter is the most important given its 
potential role in conveying disease to human. Because brucellosis is a public health 
problem, its presence and disease control strategies implemented in domestic 
ruminants affect the occurrence of disease in humans [8, 9]. In small ruminants, the 
disease is clinically characterized by a decrease in milk production, abortion, loss of 
weight, fetal death, placental retention, weak offspring, and acute orchitis. In dairy 
animals, Brucella spp. replicates in the mammary gland and supra-mammary lymph 
nodes, and infected animals continually excrete the pathogen into milk throughout 
their lives [10, 11].
In underdeveloped countries, vaccination is the main tool used in the control of 
this disease [12, 13], in particular as a preventive measure in small ruminants, and 
is considered necessary given the economic and medical consequences of having 
brucellosis in animals and people infected [14]. The main indicator of brucel-
losis reduction in animals is a concomitant reduction of human cases [13, 15]. In 
endemic areas, intensive vaccination with B. melitensis Rev. 1 strain in adult and 
young females has been developed, being the most popular vaccine for the control 
of brucellosis in small ruminants. The use of a reduced dose rate decreases the 
presence of vaccine-associated undesirable events, such as postvaccine reactors to 
conventional tests, abortion, and milk shedding [16]. The vaccination is recom-
mended prior to the first gestation between 3 and 7 months of age to avoid abortion 
in pregnant animals [17]. When used at a reduced dose, Rev. 1 has shown to protect 
goats for at least 5 years after vaccination [13, 15]. El Idrissi et al. show that after 
vaccination, the animals vaccinated with Rev. 1 became positive to rose bengal plate 
test (RBPT) and complement fixation test (CFT) at 2 weeks, reaching the highest 
number of seroconverted animals’ highest level between 2 and 6 weeks. Thereafter, 
the percentage of seropositive ewes declined to zero at 14 weeks after challenge. 
More than 75% of animals were seroconverted 15 days after challenge inoculation 
[18]. The seroconversion of vaccine is the persistent serological reaction, especially 
when animals are vaccinated as adults. These persistent serological reactions are 
mainly against the antigenic O-chain of the lipopolysaccharide present in smooth 
Brucella [19]. Some strains may generate diagnostic interferences in serological 
test [19, 20], like vaccines containing Brucella LPS O antigens that are detected by 
traditional serodiagnostic tests for brucellosis [21]. It has been reported that the 
average time from inoculation to seroconversion may range from 2 to 3 weeks in 
B. melitensis-infected goats, from 2 to 4 weeks in B. abortus-infected goats, and 
3 weeks for the majority of tests evaluated with goats infected with either Brucella 
species [5, 19].
In Mexico, the vaccine RB51 was approved since 1998 as the official one for 
use in cattle females. The strain has been evaluated in both goat and sheep under 
controlled conditions with good protection against the experimental challenge with 
B. melitensis, even though protection is lower than that obtained with the Rev. 1 vac-
cine. Under experimental conditions no abortion occurs. Also, no postvaccination 
antibodies can be detected by conventional serology. The same findings have been 
reported after mass goat vaccination with RB51 in Veracruz, Mexico [13, 15].
Nowadays, the homologous overexpression to induce a greater and more effec-
tive immune response for the improvement of protective immunity of the vaccines 
has been developed. This can be achieved by introducing a plasmid within the RB51 
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strain with the gene that encodes the antigen expressed, along with appropriate 
promoters. In mouse (Balb/c) it has been shown that the overexpression of Cu/Zn 
superoxide dismutase (SOD) induces the best protection facing the experimental 
infection by B. abortus indicating that the homologous overexpression can produce 
a better vaccine RB51 (RB51-SOD) with an equal or better protection than that 
induced by Rev. 1, against the infection with B. melitensis [14, 19, 20]. However, 
there are no reports in domestic animals on the seroconversion and the vaccine effi-
cacy. Therefore, the aim of this study was to determine the prevalence of Brucella 
melitensis in a goat flock and the seroconversion in animals vaccinated with Rev. 
1 Brucella melitensis, RB51, and RB51-SOD Brucella abortus strains to estimate the 
level of protection conferred on susceptible females.
2. Material and methods
2.1 Study design
A phase III field trial was performed from September to December 2016 in 
order to determine the seroprevalence and seroconversion of goat flocks positive to 
brucellosis in the Xaltepec community municipality of Perote, Veracruz, Mexico, 
and to evaluate the protection conferred by vaccines with Rev. 1 Brucella melitensis, 
RB51, and RB51-SOD Brucella abortus strains.
2.2 Experimental design
The experiment was performed in two stages. In the first one, 546 animals from 
14 herds with similar management, grazing, feeding, and confinement conditions 
were used to determine the prevalence of goat brucellosis in Xaltepec. In the second 
stage, groups required for vaccine evaluation were integrated by randomly selecting 
animals negative to serological tests meeting the inclusion criteria. Positive animals 
remained in the herds under field conditions in order to function as a challenge for 
healthy and vaccinated animals.
Sample size was calculated using Win Episcope Version 2.0 for simple random 
sampling, considering the 0.52% prevalence in goats reported in Veracruz by 
Román-Ramírez et al. of [12], a confidence interval of 95%, and an error margin 
of 5%. Since each animal had an identification number on its metallic earring, 
females were randomly assigned to each group and subgroup. For each group, 
the minimal calculated sample was 72 animals; each group was integrated by a 
vaccinated subgroup (36) and a not vaccinated or control subgroup (36). Studied 
groups were integrated by goats older than 3 months, seronegative to brucellosis, 
and not vaccinated previously and kept within positive flocks. Animals were ran-
domly split into three groups and kept together 8 months in the flock to maintain 
exposure to Brucella spp.
2.3 Vaccination of animals
Animals in each vaccinated group received 2 mL of vaccine subcutaneously 
applied in the neck region. The first group was injected with Rev. 1 (Brucella meli-
tensis) strain with a concentration of 1–2 × 109 CFU/mL, the second received RB51 
strain (Brucella abortus) 3 × 108 to 3 × 109 CFU/mL, and the third one was injected 
with RB51-SOD (Brucella abortus) with a concentration of 3 × 108 to 3 × 109 CFU/
mL. Each group had a control subgroup of unvaccinated animals which received 
2 mL of PSS by subcutaneous injection in the neck region.
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2.4 Sample collection
Follow-up sampling was performed at 30, 60, 90, and 365 days post vaccination 
by blood sampling collected from the jugular vein in vacutainer tubes without anti-
coagulant (BD Vacutate, Oxford, UK). Each tube was identified with the number 
in the animal earring. Tubes containing blood samples were placed in a tilt position 
about 2 hours at room temperature allowing the separation of serum from the blood 
package. Later, tubes were placed into coolers at 4°C and transported to the labora-
tory and then were centrifuged at 1000 × g 10 minutes at room temperature. Finally, 
the serum was stored in sterile vials at −20°C until analysis.
2.5 Serological testing
Serum samples were analyzed by series using the following tests: 3% RBPT as 
screening and simple radial immunodifusion test (SRD) as confirmatory [5, 22].
RBPT was used as a screening test on the serum samples collected for the pres-
ence of Brucella agglutinins. Equal volumes of test serum and B. abortus antigen 
strain 1119-3 at 3% and pH of 3.6 (Aba Test Tarjeta 3%) (National Producer of 
Veterinary Biologics PRONABIVE) were added and mixed. This test has shown 98% 
sensitivity and 100% specificity. This test gives presumptive results.
SRD was used as a confirmatory test, and the antigen was used at a concentra-
tion of 1 mg/mL on agarose gel prepared with a glycine buffer solution and native 
hapten obtained from B. melitensis 16 M strain (produced at CENID Microbiology 
Animal, INIFAP). The test has shown 96% sensitivity and 80–100% specificity 
for the differential diagnosis between goats infected with Brucella spp. and those 
vaccinated with the Rev. 1 strain.
2.6 Analyses of data
Seroconversion produced during the observation period was calculated. 
Differences between groups and the significance of association were calculated by 
chi square (Xi2), and the degree of association was estimated using relative risk 
(RR) [23]. In those cases that frequency of positive animals to tests was 0.0%, 
confidence interval was calculated according to Campbell et al. [24].
3. Results
The results of initial seroprevalence of brucellosis in goat flocks at Xaltepec are 
shown in Tables 1 and 2. The seroprevalence in the three groups determined by the 
3% RBPT as presumptive test resulted in 22.1, 26.1, and 16.0% (95%CI: 16.5–28.9, 
19.9–33.2, and 11.1–22.3, respectively).
The serum positive goats were confirmed with SRD, and the prevalence reduced 
to 0.5, 1.1, and 2.2% (95%CI: 0.3–3.4, 0.1–4.3, and 0.7–5.9, respectively). Thus, a 
general prevalence of 1.2% (95%CI: 0.5–2.7) was observed.
Tables 3–6 show the seroconversion rate in goats vaccinated with Brucella strain 
determined by RBPT at 30, 60, 90, and 365 days after vaccination. At 30 days 
after vaccination, the 77.7% (95%CI: 61.9–88.2) of goats vaccinated with Rev. 1 
strain became positive to RBPT. Thereafter, 60 and 90 days post vaccination the 
percentage of seropositive goats declined to 72.2% (95%CI: 56.0–84.1) and 63.8% 
(95%CI: 47.5–77.5), respectively. At 365 days, 13.8% of vaccinated animals remained 
as seropositive to RBPT. Only two animals vaccinated with RB51 and RB5-SOD, 
respectively, were positive to RBPT at 30, 60, and 90 days after vaccination with 
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a prevalence of 2.7% and 5.5% (95%CI: 0.4–14.1 and 1.5–18.1, respectively). At 
365 days post vaccination, only 11.1% of vaccinated animals with RB51 remained 
reacting; there were no seroreactors to RB51-SOD strain by RBPT. Meanwhile, 
animals vaccinated with RB51 and RB51-SOD did not produce anti-O side-chain 
antibodies as measured by RBPT. Non-vaccinated control goats were seronegative. 
The seroconversion of a vaccine is the persistent serological reaction, especially 
when animals are vaccinated as adults; these persistent serological reactions are 
mainly against the antigenic O-chain of the lipopolysaccharide present in smooth 
Brucella strains [20].
Tables 7–10 show positive animals to RBPT that were confirmed with the SRD 
at 30, 60, 90, and 365 days after vaccination. Only 2.7% (95%CI: 0.4–14.1) of goats 
Strain Sample size RBPT
Positive Seroprevalence (%) 95%CI
Rev. 1 185 41 22.1 16.5–28.9
RB51 180 47 26.1 19.9–33.2
RB51-SOD 181 29 16.0 11.1–22.3
Total 546 117 21.4 18.1–25.1
Table 1. 
Seroprevalence of brucellosis rate by RBPT in goat flocks of Xaltepec municipality Perote, Veracruz, Mexico.
Strain Sample size SRD
Positive Seroprevalence (%) 95%CI
Rev. 1 41 1 0.5 0.3–3.4
RB51 47 2 1.1 0.1–4.3
RB51-SOD 29 4 2.2 0.7–5.9
Total 117 7 1.2 0.5–2.7
Table 2. 
Seroprevalence of brucellosis rate by SRD in goat flocks of Xaltepec municipality Perote, Veracruz, Mexico.
Group/subgroup N Time after vaccination (days)
30
Positive Seroconversion rate (%) 95%CI
Rev 1 Vaccinated 36 28 a 77.7 61.9–88.2
Control 36 4 b 11.1 4.4–25.3
RB51 Vaccinated 36 1 a 2.7 0.4–14.1
Control 36 0 a 0.0 0.0–0.09
RB51-SOD Vaccinated 36 2 a 5.5 1.5–18.1
Control 36 0 a 0.0 0.0–0.09
Different superscripts indicate statistical difference by column (P< 0.01).
Table 3. 
Seroconvertion rates determined by RBPT at 30 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
New Insight into Brucella Infection and Foodborne Diseases
6
vaccinated with Rev. 1 became positive during the first three samplings, but this situ-
ation did not persist until at 365 days post vaccination as expected. Also, goats vac-
cinated with RB51 and RB51-SOD during the first 90 days post vaccination expressed 
Group/subgroup N Time after vaccination (days)
60
Positive Seroconversion rate (%) 95%CI
Rev 1 Vaccinated 36 27 a 72.2 56.0–84.1
Control 36 4 b 11.1 4.4–25.3
RB51 Vaccinated 36 1 a 2.7 0.4–14.1
Control 36 0 a 0.0 0.0–0.09
RB51-SOD Vaccinated 36 2 a 5.5 1.5–18.1
Control 36 0 a 0.0 0.0–0.09
Different superscripts indicate statistical difference by column (P< 0.01).
Table 4. 
Seroconvertion rates determined by RBPT at 60 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
Group/subgroup N Time after vaccination (days)
365
Positive Seroconversion rate (%) 95%CI
Rev 1 Vaccinated 36 5 a 13.8 6.0–28.6
Control 36 9 a 25.0 13.7–41.0
RB51 Vaccinated 36 4 a 11.1 4.4–25.3
Control 36 9 a 25.0 13.7–41.0
RB51-SOD Vaccinated 36 0 a 0.0 0.0–0.09
Control 36 7 a 19.4 9.7–35.0
Different superscripts indicate statistical difference by column (P< 0.01).
Table 6. 
Seroconvertion rates determined by RBPT at 365 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
Group/subgroup N Time after vaccination (days)
90
Positive Seroconversion rate (%) 95%CI
Rev 1 Vaccinated 36 23 a 63.8 47.5–77.5
Control 36 4 b 11.1 4.4–25.3
RB51 Vaccinated 36 1 a 2.7 0.4–14.1
Control 36 0 a 0.0 0.0–0.09
RB51-SOD Vaccinated 36 2 a 5.5 1.5–18.1
Control 36 0 a 0.0 0.0–0.09
Different superscripts indicate statistical difference by column (P< 0.01).
Table 5. 
Seroconvertion rates determined by RBPT at 90 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
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antibodies that were detected with the RBPT test but were negative to the SRD test; 
however, at 365 days, an animal in the RB51 strain group was identified as seropositive 
(2.7%, 95%CI: 0.4–14.1). It is noteworthy that serological samples that underwent 
Group/subgroup Time after vaccination (days)
60
Positive Prevalence rate (%) 95%CI
Rev 1 Vaccinated 1/27 2.7 0.49–14.1
Control 0/4 0.0 0.0–0.49
RB51 Vaccinated 0/1 0.0 0.0–0.79
Control 0/0 w.d.* w.d.*
RB51-SOD Vaccinated 0/2 0.0 0.0–0.66
Control 0/0 w.d.* w.d.*
*w.d.= without data
Table 8. 
Seroconversion rates determined by SRD at 60 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
Group/subgroup Time after vaccination (days)
90
Positive Prevalence rate (%) 95%CI
Rev 1 Vaccinated 1/23 2.7 0.49–14.1
Control 0/4 0.0 0.0–0.49
RB51 Vaccinated 0/1 0.0 0.0–0.79
Control 0/0 w.d.* w.d.*
RB51-SOD Vaccinated 0/2 0.0 0.0–0.66
Control 0/0 w.d.* w.d.*
*w.d.= without data
Table 9. 
Seroconversion rates determined by SRD at 90 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
Group/subgroup Time after vaccination (days)
30
Positive Prevalence rate (%) 95%CI
Rev 1 Vaccinated 1/28 2.7 0.49–14.1
Control 0/4 0.0 0.0–0.49
RB51 Vaccinated 0/1 0.0 0.0–0.79
Control 0/0 w.d.* w.d.*
RB51-SOD Vaccinated 0/2 0.0 0.0–0.66
Control 0/0 w.d.* w.d.*
*w.d.= without data
Table 7. 
Seroconversion rates determined by SRD at 30 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
New Insight into Brucella Infection and Foodborne Diseases
8
the confirmatory test (SRD) correspond to animals that had a positive result to the 
screening test (RBPT); hence, the original sample size was not decreased.
4. Discussion
Goat herds in the present study had similar conditions of feeding, handling, 
and confinement. Each group was exposed to animals infected with Brucella spp. 
Overall seroprevalence in the herds under study was 21.4% (95%CI: 18.1–25.1) with 
3% RBST as screening and 1.2% (95%CI: 0.5–2.7) by SRD as the confirmatory one. 
These seroprevalences are similar to those found by Román-Ramírez et al. in 14 
municipalities in the central area of the state of Veracruz, Mexico, that were 18.18% 
(95%CI: 15.15–21.64) by RBST and 0.52% (95%CI: 0.13–1.65) by SDR tests [12]. 
However, the seroprevalence is also greater than 9.8% reported by Solorio-Rivera 
et al. (95%CI: 8.8–10.7) [5] using RBST test in goat herds of the state of Michoacán, 
Mexico. This shows that the herds located in the community of Xaltepec, munici-
pality of Perote, Veracruz, Mexico, have animals that could be exposed to brucello-
sis and the conditions of management provide an opportunity for the perpetuating 
the infection.
The permanent vaccination program for goat herds has been operating in the 
area since 1994 achieving the requirements for the control phase according to the 
Official Mexican Standard (NOM-041-ZOO-1995) National Campaign against 
brucellosis in animals. These findings may suggest that the vaccine used is not 
protecting all animals, the vaccine is not properly managed or injected, or vaccina-
tion is not timely applied, resulting in the possibility of maintaining infection in the 
animals. Furthermore, the animal may not develop the infection, but the immune 
response capability is then detected by the diagnostic screening test without being 
a truly infected animal. As a result, the recognized agglutination serological tests 
(RSBT) leads to diagnostic confusion determining infected animals to remain in the 
herds. Hence, it is necessary to evaluate the vaccine strain to be used in the brucel-
losis control programs, since the results shown in Table 1 demonstrate that more 
than 50% of the animals reacted to the screening test, but are not infected as shown 
by the SRD test (Tables 7–9), which possess a greater sensitivity. This situation 
determines the need to invest in confirmatory tests [25–29].
When vaccinated groups of goats were evaluated by the RSBT, animals vac-
cinated with Rev. 1 strain had a seroconversion rate of 77.7% (95%CI: 61.9–88.2), 
Group/subgroup Time after vaccination (days)
365
Positive Prevalence rate (%) 95%CI
Rev 1 Vaccinated 0/5 0.0 0.0–0.43
Control 0/9 0.0 0.0–0.29
RB51 Vaccinated 1/4 2.7 0.49–14.1
Control 1/9 2.7 0.49–14.1
RB51-SOD Vaccinated 0/0 w.d.* w.d.*
Control 1/7 2.7 0.49–14.1
*w.d.= without data
Table 10. 
Seroconversion rates determined by SRD at 365 days after vaccination of goats with Rev-1, RB51, and RB51-
SOD strains in Xaltepec, Perote, Veracruz, Mexico.
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72.2% (95%CI: 56.0–84.1), 63.8% (95%CI: 47.5–77.5), and 13.8% (95%CI: 6.0–
28.6) at 30, 60, 90, and 365 days post vaccination, respectively (Tables 3–6). This 
agrees with Blasco et al. [7] who pointed out that vaccination with a full dose (1 × 
109 CFU/mL) may cause diagnostic interference and inconvenience to rely on vac-
cination as the only alternative for brucellosis eradication programs in goat herds 
[7, 27]. RBST-positive animals were confirmed by the SRD test, and only one 
animal resulted positive, representing 2.7% (95%CI: 0.4–14.1) (Tables 7–9). This 
indicates that the vaccine did not protect or that the animal was infected prior to 
vaccination, despite being negative at initial screening. Vaccinated animals were 
not challenged at a controlled dose of Brucella melitensis, since the challenge was 
through a natural exposure to the infected animals, which were kept in confine-
ment with the vaccinated animals, to allow exposed vaccinated animals to become 
infected as occurring in the normal management situation in the regional produc-
tion systems in Mexico [14, 30].
As observed in Tables 3–5, animals vaccinated with the RB51 and RB51-SOD 
strains, 2.7% (95%CI: 0.4–14.1) and 5.5% (95%CI: 1.5–18.1), respectively, reacted 
to the RBST during the evaluation period. However, when analyzed by the SRD for 
confirmation, all animals were negative. RB51 strain is officially used for vaccina-
tion only in bovine females; it is a rough mutant strain derived from B. abortus 
2308 smooth strain, so it does not induce response of anti-LPS antibodies. It has 
the advantage of allowing conventional serological tests to be used for brucellosis 
diagnosis in animals, and its use is considered safe in small ruminants [31]. Fosgate 
et al. carried out a study in water buffalo males and females which were vaccinated 
subcutaneously with RB51 at a concentration of 1.0–3.4 × 1010 UFC/mL, to evaluate 
the serological performance by agglutination tests [31]. Animals were challenged 
in a herd with an initial Brucella spp. prevalence of 56%. Out of the vaccinated 
animals, 2/32 (6.2%) reacted in different samplings in at least one serological test 
(STAT, SPAT, and/or BPAT). Authors conclude that the proportion of vaccinated 
animals that became positive to brucellosis in this field trial was greater than the 
corresponding proportion in the control group emphasizing that vaccination does 
not stop the seroconversion effect on the herds challenged with a field strain. 
Furthermore, the RB51 vaccine did not prevent seroconversion of the animals. 
Therefore, infected animals were able to process the agent and maintain such a 
condition that it could react to the diagnostic test by IgM production by stimulation 
of the O-type side chains of the field strain, although the animal was not infected 
[28, 29, 32].
El Idrissi et al. compared the vaccine efficacy of Rev. 1 and RB51 strains in sheep. 
Considering seroconversion, they conclude that after vaccination, all sheep vac-
cinated with Rev. 1 were positive to RBPT and complement fixation test (CFT) at 2 
weeks, reaching their maximum between 2 and 6 weeks [7]. Then the percentage 
decreased and was zero 14 weeks after challenge. Animals vaccinated with RB51 
did not produce anti-O side-chain antibodies, as measured by RBPT and CFT. After 
exposure to challenge, anti-O side-chain antibodies, measured by RBPT, were 
detected in the serum of vaccinated animals and controls [19].
Out of the animals vaccinated with RB51-SOD strain, 2/36 were serocon-
verted, representing 5.5% (95%CI: 1.5–18.1) (Tables 3–5). The animals that 
underwent the confirmatory test (SRD) were negative as shown in Tables 7–9. 
The above indicates that animals established an immune memory response 
generating the production of immunoglobulins detectable by the screening test, 
but they were not infected [34]. Olsen et al. [32] evaluated the RB51-SOD strain 
in bisons, which was less effective than RB51 in protecting against abortion and 
uterine infection in this species [32–34]. In the present study, some animals of 
the goat groups of B. abortus strains RB51 and RB51-SOD were positive only to 
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the screening test, which could be discarded by SRD test that identified them as 
negative to brucellosis [28, 29, 31, 33, 34].
The RB51-SOD strain was obtained from B. abortus 2308 in order to generate 
the overexpression of a protective periplasmic antigen of the protective antigen 
known as Cu/Zn SOD, which causes the immune cell response by T-helper-type Th1 
lymphocytes, and protection against the strain of B. abortus 2308, which has been 
demonstrated in murine models [26, 29, 31–33]. Despite the favorable outcome in 
mice, Dorneles et al. [33] pointed out that the potential use of RB51-SOD under 
field conditions is very limited, although satisfactory results have been obtained. It 
is important to consider that the response observed in the mice might not reflect the 
protection achieved in the natural hosts after vaccination. Moreover, to generate a 
strong and protective immune response that mimic natural infection is a complex 
challenge. However, the current study in goats allowed to evaluate the RB51-SOD 
strain and to know part of its satisfactory performance in the field, since the newly 
developed vaccines have only evaluated in murine models [28–30]. Contrary to 
the Rev. 1 vaccine, current study demonstrates that the RB51-SOD strain does not 
induce seroconversion in goats.
5. Conclusion
When evaluating the Rev. 1, RB51, and RB51-SOD vaccine strains, seroconver-
sion in animals vaccinated with Rev. 1 strain was higher than that shown by the 
strains RB51 and RB51-SOD by conventional serological tests in infected herds 
during the evaluated period. Therefore, vaccination with Rev. 1 originates the need 
to perform confirmatory tests causing an increase in diagnosis costs. According to 
results of the present study, the RB51-SOD vaccine represents an alternative for 
controlling one of the most important worldwide zoonosis in goats. However, fur-
ther studies are required to evaluate the performance of immune response, vaccine 
safety, and efficacy at field level.
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